FluMist

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

InfluenzaMemory

1053 competitors in Influenza

#DrugCompanyPhaseTrials

1

FluMist

AstraZeneca

Approved

172

Fluzone

GSK

Preclinical

373

Crestor

AstraZeneca

Preclinical

14

Trexall

Alnylam Pharmaceuticals

Preclinical

15

Quadrivalent Influenza Vaccine

Sanofi

Preclinical

306

COMIRNATY

Pfizer

Preclinical

17

Antihistamine

Arrowhead Pharmaceuticals

Preclinical

18

Focetria

CChiltern Pesquisa Clinica Ltda

Preclinical

19

Influenza A/H5N1

NNational Institute of Allergy and Infectious Diseases (NIAID)

Preclinical

1410

PD-1/PD-L1 Inhibitors

CChuangzhen Chen

Preclinical

1Show 11 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Influenza17 trials

Comparison of Inactivated and Live, Attenuated Influenza Vaccine in Children 5-9 Years of Age-Year 3 Amendment

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 4·NCT00138385·40 enrolled

Response to Live Attenuated Influenza Vaccine in Tonsillar Tissues and Blood

Withdrawn·SStanford University·Phase 4·NCT03884296

Comparative Study of Influenza Vaccines in Adults, FLUVACS-year 4

Completed·UUniversity of Michigan·Phase 4·NCT00538512·1,952 enrolled

Show 14 more trials

Laboratory Study of Licensed H1N1 Influenza Vaccines in HIV-1 Perinatally Infected Children and Youth

Completed·IInternational Maternal Pediatric Adolescent AIDS Clinical Trials Group··NCT01484522·149 enrolled

Influenza Immunity Against Pandemic Respiratory Virus

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 4·NCT00138281·60 enrolled

A Study of a Live Intranasal Influenza Vaccine in Children With Cancer

Completed·SSt. Jude Children's Research Hospital·Phase 1·NCT00906750·56 enrolled

Adaptive Immune Responses and Repertoire in Influenza Vaccination and Infection (SLVP031)

Terminated·SStanford University·Phase 4·NCT03028987·10 enrolled

T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) - Year 1, 2009

Completed·SStanford University·Phase 4·NCT01987349·72 enrolled

Study to Evaluate the Safety of a Bivalent Vaccine of New 6:2 Influenza Virus Reassortants in Healthy Adults

Completed·AstraZeneca·Phase 3·NCT00125944·300 enrolled

B-cell Immunity to Influenza (SLVP017) - Years 2 (2010) & 3 (2011)

Completed·SStanford University·Phase 4·NCT03020498·91 enrolled

Trial to Assess Safety, Tolerability, and Immunogenicity of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (FluMist) and Measles, Mumps, Rubella, and Varicella Vaccines Administered Concurrently to Healthy Children

Completed·AstraZeneca·Phase 3·NCT00192491·1,200 enrolled

Study to Evaluate the Safety of a Bivalent Vaccine of New 6:2 Influenza Virus Reassortants in Healthy Adults

Completed·AstraZeneca·Phase 3·NCT00192127·300 enrolled

Innate and Acquired Immunity to Influenza Infection and Immunization (SLVP029)

Completed·SStanford University·Phase 4·NCT03028974·77 enrolled

Tissue-specific Responses to Influenza Immunization and Their Relation to Blood Biomarkers (SLVP032)

Terminated·SStanford University·Phase 4·NCT03023709·3 enrolled

The Human Mucosal Immune Responses to Influenza Virus (SLVP026)

Completed·SStanford University·Phase 4·NCT03023553·13 enrolled

Proteomic Profiling for Influenza Vaccination - FluMist

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 4·NCT00385281·50 enrolled

Self-Administered Nasal Influenza Feasibility Study

Completed·HHenry M. Jackson Foundation for the Advancement of Military Medicine·Phase 4·NCT01933048·1,077 enrolled

Immunogenicity3 trials

A Phase I Safety and Immunogenicity Study of Mix and Match of Licensed Flu Vaccine and Flumist

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00231907·56 enrolled

Trial to Demonstrate Equivalent Immunogenicity of CAIV-T and FLUMIST in Healthy Participants

Completed·AstraZeneca·Phase 3·NCT00192335·890 enrolled

Trial to Assess the Shedding,Immunogenicity, and Safety of FluMist Administered to Healthy Individuals 5-49 Years of Age

Completed·AstraZeneca·Phase 4·NCT00192140·345 enrolled

Children2 trials

A Post Marking Study to Evaluate the Safety of FluMist in Children

Completed·AstraZeneca··NCT00569894·29,296 enrolled

A Study to Evaluate the Safety of FluMist in Healthy Children and Healthy Adults

Completed·AstraZeneca··NCT00113880·63,061 enrolled

Immunocompromised1 trial

Safety Study to Evaluate FluMist in Immunocompromised Children

Completed·AstraZeneca·Phase 1·NCT00112112·20 enrolled

CAR1 trial

Home Administration of FluMist by Parents/Caregivers

Completed·UUniversity of North Carolina, Chapel Hill·N/A·NCT01938170·41 enrolled

8 more indications

Effectiveness1 trial

Study to Evaluate the Effectiveness of FluMist Vaccination in a School-Based Intervention Program

Completed·AstraZeneca·Phase 4·NCT00192218·3,022 enrolled

Immune Response1 trial

Characterizing the Human Airway Immune Response to FluMist Vaccination

Recruiting·WWashington University School of Medicine·Phase 4·NCT07177417·30 enrolled

Vaccine1 trial

Study To Evaluate the Safety of Bivalent Vaccine

Completed·AstraZeneca·Phase 3·NCT00325481·300 enrolled

LAI1 trial

LAIV (Flumist®) Administration in CF Patients

Unknown status·MMcGill University Health Centre/Research Institute of the McGill University Health Centre··NCT01885169·170 enrolled

Immunology1 trial

Vaccine Pandemic Preparedness Through Airway Immunology Characterization

Active, not recruiting·CCopenhagen Respiratory Research·Phase 1·NCT05921448·60 enrolled

Respiratory Virus1 trial

Protective Mechanisms Against a Pandemic Respiratory Virus (SLVP024)

Completed·SStanford University·Phase 4·NCT03023683·18 enrolled

Memory1 trial

The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection

Completed·SStanford University·Phase 1·NCT03453801·80 enrolled

Unspecified1 trial

Safety Study of FluMist With and Without Ampligen

Terminated·AAIM ImmunoTech Inc.·Phase 1/2·NCT01591473·55 enrolled

Details

Drug Info

Related News